LR LIFETAKT 5in1 Beauty Elixir is the 'Winner' of the German Brand Award 2019 in the 'Beauty & Care' Category
LR Health & Beauty has started a new beauty era this year with the LR LIFETAKT 5in1 Beauty Elixir. Four months after the market launch and a sensational amount of sold 2.6 million* shots, the revolutionary product was awarded the German Brand Award 2019 yesterday. In competition with "Excellent Brands", the Elixir impressed the top-ranking jury in the "Beauty & Care" category as one of the best product brands in the industry. In addition, the Elixir also received the "Special Mention" distinction in the cross-industry category "Product of the Year", which the jury awards for special aspects in branding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005247/en/
LR Health & Beauty has started a new beauty era this year with the LR LIFETAKT 5in1 Beauty Elixir (Photo: Business Wire)
Andreas Friesch, CEO of LR Health & Beauty, is very proud of receiving this award. "Being the 'Winner' of the German Brand Award 2019 is a wonderful recognition for a very special product development. With the LR LIFETAKT 5in1 Beauty Elixir, we demonstrate our extensive health and beauty know-how in a single product. It is a reflection of our spectrum of competence and bears - like most of our products - the 'Made in Germany' seal of quality. Furthermore, the award is a motivation to continue developing pioneering innovations in the future as well.”
Excellent Beautyfood: LR LIFETAKT 5in1 Beauty Elixir
The most successful product launch in the history of the company, the LR LIFETAKT 5in1 Beauty Elixir fulfills five beauty wishes at once: youthful appearance, clear skin, firm body, healthy hair and strong nails. With just one shot a day, it ensures radiant beauty from head to toe – thanks to the unique double-complex with the most important active ingredients for beauty from science and from the power of nature. The 5in1 Beauty Elixir distinguishes itself from other beautyfood products on the market with the preventative complex that protects skin from the inside out from environmental factors and prevents the signs of ageing. Moreover, the active complex activates the beauty process in the body, ensuring radiant beauty from head to toe - no matter the age of the person using it. The Elixir has a fruity-fresh taste and is free of sweeteners, artificial colours, lactose and gluten.
The direct sales method with trained, independent sales partners who introduce and sell products in a professional manner with a high consultation level, is crucial to the success of the product.
German Brand Award | German Design Council
The German Brand Award is a prize offered by the German Design Council and the German Brand Institute, crowning the most innovative brands, consistent branding, and sustainable brand communication. It is divided into two competitions: "Excellent Brands" awards the best product and company brands in an industry. "Excellence in Brand Strategy and Creation" honours the strongest campaigns, concepts and strategies in individual disciplines.
The German Design Council is an independent and internationally active institution that assists companies to efficiently communicate design and brand competence, while at the same time aiming to strengthen the general public's understanding of design. Established as a foundation in 1953, at the initiative of the German Bundestag by the Federation of German Industries and several leading companies, the German Design Council supports the advancement of design and branding with its competitions, exhibitions, conferences, seminars and publications. Currently, over 300 companies both inland and abroad belong to the circle of founders of the German Design Council. More information: german-brand-award.com
LR Health & Beauty
With its "More quality for your life" campaign, the LR Group, with headquarters in Ahlen, Westphalia, produces and markets various beauty and health products in 28 countries. The products include care and decorative cosmetics, dietary supplements and perfume. The processing of aloe vera has been one of LR Health & Beauty's key areas of expertise for over 15 years, whereby the precious inside of the leaf is exclusively used. With an annual volume of 12,000 tons of aloe vera leaves, today the company is one of the largest manufacturers of aloe vera products worldwide. With 1,100 employees and thousands of registered Sales Partners and clients, LR is one of the leading direct sales companies in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005247/en/
Contact information
LR Health & Beauty
Almut Kellermeyer
Head of PR / Public
Affairs
Tel.: +49 2382 7060-106
E-mail: A.Kellermeyer@LRworld.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing